(CercleFinance.com) – Roche announces statistically and clinically significant results from its phase III STARGLO study, demonstrating that Columvi significantly prolongs the survival of people with relapsed or refractory diffuse large B-cell lymphoma.
The study indeed met its primary endpoint of overall survival with a 41% reduction in the risk of death in patients treated with Columvi plus GemOx chemotherapy, compared to MabThera/Rituxan in combination with GemOx.
‘This Columvi combination could constitute an essential ready-to-use treatment option for people with relapsed or refractory DLBCL not eligible for transplant,’ underlines the Swiss healthcare giant.
These data were presented at the press conference and presented during the abstract plenary session of the European Hematology Association (EHA) Congress 2024 as a late-breaking oral presentation.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
